Veru Inc. Showcases Innovations at International Conference
MIAMI, FL, Dec. 04, 2025 — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company committed to developing cutting-edge treatments for cardiometabolic and inflammatory diseases, has announced several key presentations at The Society on Sarcopenia, Cachexia, and Wasting Disorders (SCWD) 18th International Conference and the accompanying Regulatory and Clinical Trials Update Workshop.
Key Presentations at the SCWD Conference
The 18th International Conference focuses on significant advancements in understanding and treating conditions such as muscle wasting associated with obesity. One of the pivotal sessions will be led by Mitchell Steiner, the Chairman, President & CEO of Veru Inc.
Program Session P: Weight Loss Drugs and Cardiovascular Health
Mitchell Steiner will present on December 12, 2025, discussing "The Veru Experience," which emphasizes innovative strategies in weight loss management to enhance cardiovascular health. This session aims to provide insights into Veru’s unique approaches and findings in ongoing clinical trials.
Round Table Discussion on Novel Therapies
On December 13, 2025, Steiner will also lead a round table under Program Session U, focusing on novel strategies to combat sarcopenia while addressing obesity. His presentation will delve into the novel compound, enobosarm, showcasing its potential in changing therapy outcomes.
Insights from the Regulatory Workshop
This workshop is designed to highlight innovative therapeutic approaches for addressing muscle wasting during obesity therapy. Related discussions will feature industry leaders who will share their insights and the latest developments in regulatory considerations.
Combating Muscle Wasting in Obesity Therapy
Veru's approach aims to prevent and counteract skeletal muscle loss during incretin therapy. Steiner’s insights will underscore the effectiveness of drugs, trial designs, and benchmarks for success within this therapeutic landscape. The session is scheduled for December 11, 2025.
Potential Endpoints for Approval
Also on December 11, 2025, a session will focus on reviewing potential endpoints needed for regulatory approval for muscle-wasting treatments in obesity. Discussions on the regulatory approach will involve key considerations to enhance the approval pathways for innovative therapies.
About Veru Inc.’s Innovative Drug Development
Veru has successfully pioneered the development of novel small molecules aimed at treating cardiometabolic and inflammatory diseases. Among these, enobosarm represents a significant advancement in selective androgen receptor modulators (SARMs), enhancing targeted fat loss while preserving lean muscle mass. This innovative therapy aims to improve body composition and overall physical function.
Enobosarm: Transformative Approaches to Weight Loss
Veru's Phase 2b QUALITY clinical study showcased enobosarm’s role in maximizing fat loss while maintaining muscle integrity, particularly among older adults undergoing treatment with semaglutide (Wegovy). The outcomes from this trial bolster the company’s commitment to refining obesity therapy approaches.
Planned Phase 2b PLATEAU Clinical Study
The upcoming Phase 2b PLATEAU study will investigate enobosarm’s efficacy in large-scale obesity treatments while prioritizing patient safety and physical function enhancement. Targeting a participant group of approximately 200, this study promises vital insights into overcoming weight-loss plateaus associated with GLP-1 RA treatments, slated to begin in early 2026.
Conclusion and Corporate Information
Veru Inc. is dedicated to advancing its clinical initiatives, focusing on treatments that offer resilience and transformation for individuals battling obesity and related complications. For more information on their latest developments, investors and interested parties are encouraged to contact:
Investor and Media Contact:
Samuel Fisch
Executive Director, Investor Relations and Corporate Communications
Email: veruinvestor@verupharma.com
Frequently Asked Questions
What is the focus of Veru Inc.?
Veru Inc. focuses on developing innovative medicines for cardiometabolic and inflammatory diseases.
What presentations is Veru Inc. conducting at the SCWD conference?
Veru Inc. will present sessions on weight loss drugs, and novel strategies for treating obesity-induced muscle wasting.
What is enobosarm?
Enobosarm is a selective androgen receptor modulator designed to enhance fat loss while preserving lean body mass.
What does the Phase 2b PLATEAU clinical study aim to achieve?
The study aims to evaluate enobosarm's effects on total body weight and physical function in patients with obesity.
How can I learn more about Veru Inc.'s developments?
For updates and information, interested individuals can reach out via email or visit the corporate website.
